Free tool
FAERS Monitor: Zembrace Symtouch (Autoinjector)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208223 or its brand name (Zembrace Symtouch (Autoinjector), Sumatriptan Succinate). Reports on generic versions are filed under their own applications.
Reports
7,926
Serious
3,886
49% of reports
Hospitalization
1,391
Death reported
216
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,185
- headache793
- migraine664
- nausea591
- product dose omission issue574
- fatigue503
- off label use456
- product quality issue433
- device malfunction404
- pain383
- dizziness371
- product complaint349
- drug intolerance335
- dyspnoea321
- vomiting300
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 47 |
| 2005 | 54 |
| 2006 | 57 |
| 2007 | 99 |
| 2008 | 81 |
| 2009 | 175 |
| 2010 | 425 |
| 2011 | 296 |
| 2012 | 195 |
| 2013 | 148 |
| 2014 | 170 |
| 2015 | 213 |
| 2016 | 444 |
| 2017 | 294 |
| 2018 | 377 |
| 2019 | 387 |
| 2020 | 565 |
| 2021 | 524 |
| 2022 | 558 |
| 2023 | 695 |
| 2024 | 664 |
| 2025 | 602 |
| 2026 | 856 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,233 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product complaintSignal | 349 | 37.0 | 33.4 | 12,051 |
| migraineSignal | 664 | 18.6 | 17.3 | 11,001 |
| device malfunctionSignal | 404 | 15.3 | 13.9 | 5,388 |
| drug intoleranceSignal | 335 | 9.2 | 8.3 | 2,453 |
| product quality issueSignal | 433 | 8.5 | 7.7 | 2,860 |
| product dose omission issueSignal | 574 | 5.2 | 4.8 | 1,960 |
| headacheSignal | 793 | 3.4 | 3.1 | 1,350 |
| drug ineffectiveSignal | 1,185 | 2.4 | 2.3 | 1,017 |
| nausea | 591 | 2.0 | 1.8 | 298 |
| dizziness | 371 | 2.0 | 1.8 | 182 |
| fatigue | 503 | 1.7 | 1.6 | 155 |
| vomiting | 300 | 1.7 | 1.5 | 86 |
| pain | 383 | 1.7 | 1.5 | 102 |
| dyspnoea | 321 | 1.5 | 1.4 | 55 |
| off label use | 456 | 1.4 | 1.3 | 50 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.